4 Advanced Cancer Therapies.
One Clear Comparison.
We break down CAR-T, TIL, NK Cell, and Gamma Delta T-cell therapies — what they treat, what they cost, and which patients actually qualify. No marketing. Just peer-reviewed data, real costs, and honest timelines.
Find Your Therapy Match in 30 Seconds
Answer three questions. Get an evidence-based recommendation — no registration required.
CAR-T vs TIL vs NK Cell vs Gamma Delta
Ten critical dimensions compared. Green = strongest evidence/access. Yellow = moderate. Red = limited.
| Dimension | 🧬 CAR-T | 🔬 TIL | 🛡️ NK Cell | ⚔️ Gamma Delta |
|---|---|---|---|---|
| Cancer Type | Hematologic (ALL, DLBCL, MM) | Melanoma, Cervical, some solid | Blood + adjuvant solid | Solid (lung, liver, pancreas) |
| FDA / NMPA Approval | FDA (6 products) + NMPA (3) | FDA (Amtagvi, 2024) | No full FDA approval | Research use in China |
| Cost Range | $50K (China) – $475K (USA) | $80K – $120K (China/SG) | $20K – $50K | $30K – $60K |
| Response Rate | 70–90% (B-ALL) | 36% ORR (melanoma) | 35–50% | 40–60% disease control |
| Wait Time | 4–8 weeks | 6–10 weeks | 2–4 weeks | 3–5 weeks |
| Best Country | China (700+ trials) | China / Singapore | China / India | China |
| Side Effects | CRS (managed), ICANS (rare) | Lymphodepletion, fatigue | Mild, low CRS risk | Very mild, no HLA match |
| Trial Availability | 700+ (ClinicalTrials.gov) | 150+ trials | 80+ trials | 60+ trials (mostly China) |
| Off-the-shelf? | Autologous only | Autologous only | Yes (allogeneic) | Yes (allogeneic) |
| Best Patient Profile | Relapsed B-cell malignancy, ECOG 0–2 | Advanced melanoma post-PD-1 | Adjuvant or low-burden disease | Solid tumors, no HLA match needed |
Each Therapy, Explained Honestly
Mechanism, eligibility, real-world numbers, costs, and limitations — written for patients and reviewed by oncologists.
Your T-cells are collected via apheresis, shipped to a lab where a chimeric antigen receptor (CAR) is added, expanded over 2–3 weeks, then reinfused after brief chemotherapy. The engineered cells seek and destroy cancer cells expressing the target antigen (CD19, BCMA, etc.).
- Relapsed/refractory B-cell ALL, DLBCL, follicular lymphoma, mantle cell lymphoma, or multiple myeloma
- Failed ≥2 prior lines of therapy
- ECOG performance status 0–2
- Adequate cardiac, pulmonary, hepatic, renal function
ORR 70–90% in B-cell ALL; CR 50–60% in DLBCL; durable remission >24 months in ~40% of responders.
Maude et al., NEJM 2023; Neelapu et al., Lancet 2022| China (NMPA-approved) | $50,000 – $80,000 |
| Turkey | $90,000 – $130,000 |
| India | $60,000 – $95,000 |
| Germany | $180,000 – $250,000 |
| USA (Kymriah/Yescarta) | $375,000 – $475,000 |
4–8 weeks from medical record submission to infusion. Manufacturing takes 3 weeks; lymphodepletion and monitoring require 2–3 weeks in-country.
- Cytokine Release Syndrome (CRS): Fever, hypotension — occurs in 70–90%, usually Grade 1–2, managed with tocilizumab
- ICANS (neurotoxicity): Confusion, aphasia — 20–30%, mostly reversible
- Prolonged cytopenias: 30–40%, may require G-CSF or transfusions
A piece of your tumor is surgically removed. TILs naturally present in the tumor are isolated and expanded in IL-2 over 3–5 weeks to reach billions of cells. After lymphodepleting chemotherapy, the TILs are reinfused, followed by short-course IL-2 to sustain them.
- Unresectable or metastatic melanoma progressing after PD-1 inhibitor (and BRAF/MEK if BRAF-mutated)
- Cervical cancer (investigational, post-chemotherapy)
- ECOG 0–1, adequate organ function, resectable tumor site for TIL harvest
ORR 36% in advanced melanoma (C-145-04 pivotal trial); CR 11%; responses durable beyond 2 years in many patients.
Lifileucel, NEJM 2023; FDA approval Feb 2024| China | $80,000 – $120,000 |
| Singapore | $100,000 – $150,000 |
| USA (Amtagvi) | $375,000+ |
| Germany / Turkey | Limited availability |
6–10 weeks. Surgical tumor harvest → 3–5 week manufacturing → lymphodepletion → TIL infusion → IL-2 support (up to 12 doses).
- Lymphodepletion effects: Prolonged cytopenias, infection risk (1–2 weeks)
- IL-2 toxicity: Capillary leak syndrome, hypotension, requires ICU-capable monitoring
- Fatigue, fever: Common, usually manageable
NK cells are either collected from the patient (autologous) or from healthy donors (allogeneic), expanded ex vivo with cytokines (IL-2, IL-15), and reinfused. They recognize and kill cancer cells without prior sensitization or HLA restriction, using activating/inhibitory receptor balance.
- Hematologic malignancies (AML, ALL, lymphoma) — often as consolidation or post-transplant
- Solid tumors — adjuvant setting after surgery/chemotherapy
- ECOG 0–2; fewer strict eligibility barriers than CAR-T
ORR 35–50% in hematologic malignancies; as adjuvant therapy, NK infusion associated with improved DFS in some studies. Evidence is promising but less mature than CAR-T.
PubMed meta-analyses 2022–2025| India | $20,000 – $40,000 |
| China | $30,000 – $50,000 |
| Thailand / Turkey | $35,000 – $60,000 |
| Germany / USA | Mostly clinical trials |
2–4 weeks. Allogeneic (off-the-shelf) products allow rapid scheduling; autologous requires 2–3 week expansion.
- Mild infusion reactions: Fever, chills (rarely Grade ≥2)
- Very low CRS risk compared to CAR-T
- No ICANS reported in major series
- GvHD risk minimal with allogeneic NK (unlike T-cells)
Gamma Delta (γδ) T-cells recognize stress-induced molecules on cancer cells without MHC restriction — meaning they don't need HLA matching and can target a broad range of tumors. They are expanded ex vivo (often using zoledronate or IL-2) and reinfused, sometimes combined with bispecific antibodies.
- Solid tumors: lung, liver (HCC), pancreatic, colorectal, renal
- Patients without targetable mutations for CAR-T
- ECOG 0–2; no strict HLA requirements
40–60% disease control rate in phase I/II solid tumor trials; objective responses lower (~15–25%) but stable disease often durable. Best used in combination with other modalities.
PubMed γδ T-cell trials 2020–2025| China | $30,000 – $60,000 |
| Thailand | $40,000 – $70,000 |
| Japan | Research setting only |
| USA / EU | Early-phase trials only |
3–5 weeks. Collection → expansion → infusion; can be repeated in cycles depending on protocol.
- Very mild: transient fever, fatigue
- No HLA matching needed — allogeneic use safe
- No ICANS reported
- Minimal CRS — outpatient infusion often possible
Which Country for Which Therapy
Based on approval status, trial density, cost, and CancerCareE network strength.
Clinical Reference: Eligibility & Protocol Summary
Quick-reference criteria for referring oncologists. Peer case review available within 48 hours.
CAR-T Eligibility
- ECOG
- 0–2
- Prior therapy
- ≥2 lines, relapsed/refractory
- Contraindications
- Active infection, severe autoimmune, LVEF <40%
- Protocol
- Apheresis → manufacture 3 wks → lymphodepletion (Flu/Cy) → infusion → 2-wk monitoring
TIL Eligibility
- ECOG
- 0–1
- Prior therapy
- PD-1 ± BRAF/MEK progressed
- Contraindications
- No resectable tumor site, severe cardiopulmonary disease
- Protocol
- Tumor resection → 3–5 wk expansion → lymphodepletion → TIL + IL-2 (up to 12 doses)
NK Cell Eligibility
- ECOG
- 0–2
- Prior therapy
- Flexible — adjuvant or active disease
- Contraindications
- Few — mainly uncontrolled infection
- Protocol
- Allogeneic infusion (off-the-shelf) or autologous (2–3 wk expansion); outpatient-capable
Gamma Delta Eligibility
- ECOG
- 0–2
- Prior therapy
- Solid tumors post-standard therapy
- Contraindications
- Minimal — no HLA match required
- Protocol
- Expansion with zoledronate/IL-2 → infusion cycles; often combined with checkpoint inhibitors
Refer your patient directly. Our medical coordination team provides peer-to-peer case review and center matching.
Physician Referral PortalQuestions Patients Actually Ask
Honest answers, cited sources, no marketing language.
CAR-T is a type of immunotherapy, but it is autologous (made from your own cells) and genetically engineered to target cancer. Traditional immunotherapies like checkpoint inhibitors (e.g., pembrolizumab) are off-the-shelf drugs that help your existing immune system recognize cancer. CAR-T is typically reserved for hematologic malignancies, while checkpoint inhibitors are used across many solid tumors.
CAR-T is FDA/NMPA-approved for relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, and multiple myeloma. Patients typically must have failed at least 2 prior lines of therapy, have an ECOG performance status of 0-2, and have adequate organ function. Active infections or severe autoimmune disease may be contraindications.
In the USA, FDA-approved CAR-T products (Kymriah, Yescarta) cost $375,000-$475,000 due to R&D recoupment, hospital facility fees, and prolonged inpatient monitoring. In China, domestically developed CAR-T therapies (e.g., relmacabtagene autoleucel) are approved by NMPA and priced at $50,000-$80,000 due to lower manufacturing costs, shorter hospital stays, and government price negotiation. Clinical outcomes in Chinese trials are comparable to US pivotal trials (ORR 79-89%).
CAR-T has shown limited efficacy in solid tumors due to the tumor microenvironment, antigen heterogeneity, and T-cell exhaustion. As of 2026, no CAR-T product is FDA-approved for solid tumors, though clinical trials are ongoing for mesothelin-positive cancers, glioblastoma, and hepatocellular carcinoma. For solid tumors, TIL therapy (FDA-approved for melanoma in 2024) and Gamma Delta T-cell therapy show more promise.
In the C-145-04 pivotal trial (NEJM 2023), lifileucel (Amtagvi) achieved an objective response rate of 36% in advanced melanoma patients who had progressed on PD-1 inhibitors and, if BRAF V600-mutated, a BRAF inhibitor ± MEK inhibitor. Complete responses were observed in 11% of patients, with durability of response exceeding 2 years in many responders. It was FDA-approved in February 2024.
As of June 2026, no NK cell therapy has received full FDA approval for cancer treatment. However, several NK cell products are in Phase 2/3 clinical trials (e.g., FT516, FT596 from Fate Therapeutics). In China, NK cell therapy is offered as a medical technology under NMPA regulatory frameworks, primarily in clinical research settings or as adjunctive therapy. It is widely used in China, Japan, and Southeast Asia for hematologic malignancies and as adjuvant therapy post-surgery.
From medical record submission to first infusion, the typical timeline is 4-8 weeks: Week 1 — medical review and eligibility confirmation; Week 2-3 — apheresis (cell collection) and shipping to manufacturing facility; Week 3-6 — manufacturing and quality control; Week 6-7 — lymphodepleting chemotherapy (fludarabine/cyclophosphamide); Week 7-8 — CAR-T infusion and monitoring for cytokine release syndrome (CRS).
Yes. We have a dedicated Physician Referral Portal at cancercaree.com/for-physicians/. Your oncologist can submit case details, and our medical coordination team will provide a peer-to-peer case review within 48 hours, including treatment recommendations, center matching, and cost estimates. We facilitate direct communication between your treating physician and the destination center's medical team.
Not Sure Which Therapy Fits Your Case?
Submit your medical records. Our oncology team reviews every case personally and responds within 48 hours with a clear recommendation — free.
Find My Treatment Options